Abstract
The high mortality and morbidity rate of stroke is a chronic problem that plagues human society. The activation of microglia is one of the principal reasons why neuroinflammation induces cerebral dysfunction. Because of their vital functions in the regulation of neuroinflammation, microglia constitute an important target for stroke. Given that there is an innate self-preservation mechanism between neurons and microglia, the transmembrane glycoproteins on the surface of their membranes, namely CD200 and CD200R, have become a popular topic of research. Numerous studies have demonstrated that CD200-CD200R interaction, microglial activation, and poststroke neuroinflammatory damage are inextricably linked. In this review, we describe the above relationship from a new perspective. We specifically focus on neuroinflammation after stroke. The role of crosstalk of CD200-CD200R inhibitory immune ligand receptors in immune regulation will also be illustrated. Thus, we will see how poststroke injury can be influenced by the CD200-CD200R crosstalk. Finally, we will discuss the possibility of clinical application of the result of CD200-CD200R interaction to manage neuroinflammatory injury after stroke.
Introduction
Stroke with high mortality and morbidity rates have a high incidence worldwide and threatens human health and quality of life. It is a devastating disease and continues to play an important role in current research in the field of medicine. Portegies, from the Epidemiology Department of Erasmus MC University Medical Center, found that between 1990 and 2012, 74.3% of patients with their first-ever stroke died (919/1237), but only 53.8% of stroke-free participants died (2654/4928) (). Stroke is classified into two types: ischemic stroke and hemorrhagic stroke. The former accounts for over 80% of stroke cases (). In recent years, several therapeutic strategies for stroke have been used in clinical practice. Unfortunately, most patients are unable to obtain timely and proper treatment because of the narrow therapeutic time window, and only 3.4–5.2% of patients receive timely treatment during the acute phase (). During the subacute and chronic phases, it is therefore quite essential to discover other combinations of treatments to facilitate the functional rehabilitation of patients with stroke ().
Following the use of the magnetic resonance imaging (MRI) techniques at the cellular and molecular level, researchers have obtained a new understanding of the inflammatory reaction after stroke because of the ability to dynamically monitor the reaction changes occurring at spatial and temporal levels (). The immune response after stroke is a significant factor that affects the pathobiology and prognosis of acute ischemic stroke (). Microglia/macrophages are the main immune cells in the defense against brain damage (). These cells release mediators, which may have positive effects on brain repair and neurogenesis. Furthermore, superabundant proinflammatory mediators can cause secondary neuronal injury and hinder brain regeneration ().
CD200 and its receptor CD200R are transmembrane glycoproteins present on the surface of cells. Studies have shown that CD200 is expressed on the surface of a wide variety of cells such as thymocytes, B cells, T cells, tonsil follicles, kidney glomeruli, syncytiotrophoblasts, and endothelial cells (). Indirect immunoperoxidase staining showed that CD200 is primarily distributed in all neurons of the spinal cord and brain in the central nervous system (). CD200R is expressed to a lesser extent than CD200 and is mainly distributed in myeloid cells (). In the central nervous system, CD200R is mainly expressed in microglia (). CD200R1, a member of the CD200R family, binds to CD200 with a higher affinity than other CD200R family members (). Recently, we have focused our attention on the relationship between CD200 and CD200R to elucidate their immunoregulatory functions in neuroinflammation.
Neurons are thought to have a self-protection mechanism in which they express CD200 that binds to CD200R on the microglial surface, which further prevents secondary neuronal injury caused by microglia (; ; ). Although there are no studies on the specific repair mechanisms and therapeutic effects of CD200-CD200R in poststroke inflammation injury, CD200R, could still be considered as a high potential target in the study of stroke immunotherapy.
Neuroinflammation After Stroke
The innate immune system plays a role in the cerebral damage due to ischemia, hemorrhage, and other brain injuries, and inflammatory signal transduction is involved in all periods of stroke, from the early stages where it mainly causes damage to the late regenerative processes responsible for brain tissue repair (). After stroke, primary brain damage results from the death of cerebral cells. Secondary brain damage is caused by cytoplasmic substances released into the extracellular environment, which initiate a cascade of inflammatory events that can amplify cell damage (). Microglia have profound effects on neuroinflammation. Activated microglia act as a double-edged sword. These cells are normally responsible for clearing up necrotic neural cells and restoring neuronal functions. However, when overly activated after stroke, they produce a high amount of proinflammatory mediators that can destroy the blood-brain barrier and neurons and affect neurogenesis (). In this review, we have mainly focused our attention on the proinflammatory functions of microglial activation closely linked to the regulator CD200-CD200R.
Mechanisms of Microglial Activation
During the occurrence of acute brain injuries, microglia shift their activated states depending on two factors: the expression of “on signals” and/or the abnormity of “off signals” (). The “On” signal is principally found in pathological states and involves purines, chemokines, matrix metalloproteinase-3, and glutamate. The “Off” signal mainly appears in the healthy brain and is regulated by the release of CD22, CX3CL1, neurotrophins, and neurotransmitters from neural cells, which could combine with receptors on microglia and help microglia to function in the physiological process ().
Immediately after the occurrence of cerebral injuries, microglia become activated through signals. Damage-associated molecular patterns (DAMPs), which include modified extracellular matrix components, modified or oxidized lipid species, DNA, RNA, and cytoplasmic proteins, are released from the cell intracellular structures at the appropriate time of cell death (). DAMPs activate families of scavenger receptors and Toll-like receptors on microglia, thereby triggering stroke-induced neuroinflammation. In particular, Toll-like receptor 4 (TLR4) and TLR2 are considered to mediate the inflammatory response involved in the pathophysiological processes of cerebral ischemia-induced injury (). Mice lacking TLR4 showed less expression of mediators relevant to brain damage and inflammation, including IFN-β, COX2, inducible nitric oxide synthase (iNOS), interferon regulatory factor-1(IRF1), and matrix metalloproteinase-9 (MMP-9) (). Moreover, ATP from injured neurons, a type of DAMPs, is a contributing factor that causes microglia to function by binding to the purinergic receptors on microglia ().
Proinflammatory Functions of Microglial Activation
Once microglia are activated, they undergo major changes in their morphology, functions, and behaviors, such as migration, proliferation, and phagocytosis. The production of proinflammatory cytokines such as IL-6, IL-1, and TNF-α is one of the most crucial abilities of microglia (). Furthermore, activated microglia synthesize iNOS, which is essential to produce NO. High levels of NO damage the brain under the oxidative stress state because of the oxidation and nitro-tyrosination of useful substances (). On the one hand, the proinflammatory cytokines lead to neuronal death through direct or indirect pathways, for instance, apoptosis and necrosis regulated by the caspase family of proteins and inflammasome (; ). On the other hand, the proinflammatory cytokines could mediate the phagocytic activity of microglia. After ischemic stroke, higher levels of TNF-α expression were detected in accordance with higher phagocytic activity of microglia (). TNF-α has strong immune activity and neurotoxicity ().
Role of the CD200-CD200R Interaction in Neuroinflammation
One of the most useful endogenous immunoregulatory molecule candidates that could prevent the neuroinflammation status of the brain tissue seriously altered in cerebral injuries is the CD200/CD200R inhibitory immune ligand-receptor crosstalk. The immunomodulatory effect of CD200-CD200R is produced in the different processes of microglial functions, as shown in the following text.
Impact on Microglial Proliferation
In this segment, the proliferation of microglia probably affected by the CD200-CD200R interaction is discussed. found that in a CD200-deficient mice model with toxoplasma encephalitis, the number of microglia with the proliferation-associated antigen Ki67 + dramatically increased; this finding demonstrates that the deficiency of the CD200-CD200R interaction upregulates microglial proliferation. Furthermore, a study by showed a high amount of microglia following the exposure to rotenone in the neuron-microglia co-cultures after using an anti-CD200R blocking antibody (ACDR). observed an increase in the quantity of microglial cells with active phenotype by using a retinoic acid (RA)-induced spina bifida animal model to downregulate CD200 and upregulate CD200R. Thus, it can be speculated that the loss of the CD200-CD200R pair will stimulate microglial proliferation.
Influence of Microglial Activation
One of the most pivotal roles played by the CD200-CD200R interaction is in maintaining microglia in a resting state to inhibit the release of the proinflammatory mediators. As shown in Figure 1, once CD200R binds to CD200, its tyrosine residues are phosphorylated. Simultaneously, the downstream of tyrosine kinase (DOK)1, DOK2, and RAS p21 protein activator 1 (RasGAP) are recruited. Finally, MAPK p38, extracellular kinase (ERK), and c-Jun terminal kinase (JNK), the common signaling pathways in microglial activation, are suppressed (). Ultimately, the production of TNF-α, IL-6, and iNOS is reduced (). In one study, the authors used mice lacking CD200 to reveal that microglia exhibited a more activated phenotype and were large in numbers (). observed that the level of proinflammatory cytokines increased using a selective blocking antibody against CD200R1; this finding indicates that the destruction of CD200R1 induced microglial cells to exhibit a proinflammatory phenotype. administered a CD200R1 agonist (CD200Fc) in mice with experimental autoimmune encephalomyelitis (EAE) during the chronic phase of the disease; they found that the activation markers of microglia were decreased. To the best of our knowledge, we can predict that the immunomodulatory outcome of CD200-CD200R binding is to inhibit the activation of microglia.
FIGURE 1
Role of CD200-CD200R in Stroke
Stroke leads to the death of neural cells. In this condition, the CD200-CD200R has ceased to function. Although understanding the interaction between microglial cells and neurons is a significant challenge, it has a high therapeutic potential to restore damage caused by microglia in neuroinflammation after stroke. For the past few years, various studies have been conducted on CD200-CD200R interaction in stroke in animal models, and satisfactory results have been achieved.
Effects on Microglial Activation by Mechanisms
showed CD200 could open the KATP channel (adenosine triphosphate-sensitive potassium) and inhibit the release of ATP as well as the proinflammatory factors in an in vitro Parkinson’s disease (PD) model. Thus, it can be said that the CD200/CD200R inhibitory immune ligand-receptor system partially mediates the inhibitory effects of microglial activation by reducing ATP release. Additionally, a report demonstrated that the fusion protein CD200-Fc reduced the levels of TLR4 on the surface of peripherally circulating macrophages in an in vivo model of white matter ischemia induced by endothelin-1 (). On the basis of these results, we can speculate that the same process occurs in the microglia. In a recent study, researchers developed animal models with acute stroke by subjecting the wild-type (WT) control mice and CD200R1-knockout (KO) littermate mice to 60 min transient middle cerebral artery occlusion (tMCAO) and assessed post-acute changes in monocyte infiltration, microglia proliferation, and behavioral deficits up to 1 week. Surprisingly, at 72 h after stroke, more deaths occurred in the CD200R1-deficient mice group because of monocyte infiltration and exacerbated microgliosis. On the seventh day, CNS inflammation was resolved in WT mice, whereas microglia activation persisted in CD200R1-KO mice ().
Correlations With Stem Cell Treatment in Stroke
Cell therapy represents a potential breakthrough in the treatment of stroke. Preclinical studies have revealed that cell therapy is effective in the improvement of sensorimotor functions and facilitation of behavioral recovery in animal models of stroke (). More importantly, the putative mechanisms include neuroprotection against inflammation.
In a previous study, the authors used an in vitro human allogeneic co-culture model to reveal the interplay between neural stem/progenitor cells (NPCs) and a microglia population. They showed that the proportion of NPCs expressing CD200 and microglia expressing CD200R in the co-culture were higher than those in the mono-culture, leading to the enhanced possibility of the CD200 ligand-receptor binding to ameliorate the detrimental neuroinflammation mediated by microglia (). In addition, proved that human placenta amniotic membrane-derived mesenchymal stem cells (AMSCs), transplanted into the rat model with ischemic stroke, drastically reduced the level of proinflammatory cytokines accompanied by upregulation of the CD200 protein and suppressed microglia activation compared to the control group. Furthermore, several experiments confirmed that transplantation of various stem cells had anti-inflammatory effects in the treatment of stroke, although the results did not explicitly state that the regulation of inflammation was induced by CD200-CD200R because of the inadequate analysis of CD200 distributed on the surface of stem cells (; ; ). It is, however, still reasonable to believe that there is a relationship between the two on a theoretical basis. More research studies are needed to gain further knowledge on this topic.
CD200-CD200R in Other Neuronal Injuries
The EAE model is used to investigate the relationship between CD200-CD200R and multiple sclerosis (MS). In the experiment, the phenomenon of reduction in CD200 and an increase in CD200R1 was observed in the EAE model. More specifically, CD200 expression showed an apparent reduction before the appearance of clinical symptoms in EAE. This perhaps indicates that changes in CD200 expression might occur in the early phase of MS, which may be the reason for the downregulated control of macrophage/microglial activation, thus contributing to the inflammatory response and the development of pathological processes. In comparison, a succedent increase in CD200R1 expression followed behind that seemingly portended compensatory reaction to re-build control of the inflammation ().
The CD200-CD200R pair also acts as a contributing factor to neurodegenerative diseases such as PD and Alzheimer’s disease (AD). After preinjection of a CD200R blocking antibody to block the CD200-CD200R inhibition signal in rats, a sub-lethal dose of 6-hydroxydopamine, which only caused slight death of dopaminergic neurons in the substantia nigra, resulted in apparent PD symptoms in rats. Histopathological examination showed the death of dopaminergic neurons and activation of microglia cells in the substantia nigra (). Quantitative studies demonstrated significantly less mRNA and protein levels of CD200 and CD200R in the inferior temporal gyrus and hippocampus (brain regions that show significant AD pathology) from the neuropathologically confirmed AD samples; however, a similar result was not observed in cerebellum samples – an encephalic region that is spared of AD pathology in general ().
Conclusion and Future Prospects
Recently, CD200 and CD200R have been increasingly investigated, and the immune regulation induced by the CD200-CD200R axis is valuable. As we already know, the toxic damage caused to neurons by overactivated microglia far outweighs its benefits (; ). Nonetheless, neurons have a self-protection mechanism in which they express CD200 that binds to CD200R on the microglia surface, leading to the negative regulation of proinflammatory factors derived from microglia (). Although there are no studies on the specific repair mechanisms and therapeutic effects of CD200-CD200R in poststroke inflammation injury, CD200R can still be considered a high potential target in the study of stroke immunotherapy.
In accordance with the evidence reviewed earlier, stem cells are optimal materials for the cell therapy of patients with stroke. Many animal trials have been conducted, in which the anti-inflammatory effects of stem cells are hot topics (; ; ). Yet, some questions remain unsolved. Which kind of stem cell can convert into neurons and express more CD200? Will a combination of stem cells be more effective or less effective? Do stem cells have other signaling pathways that could help enhance the anti-inflammatory regulation of CD200-CD200R interaction? Can we find a method to make the surviving neurons compensate for the high expression of CD200? Or is it possible to use the fusion protein CD200-Fc as a method to treat the harmful neuroinflammation induced by microglia?
In conclusion, compared to traditional treatment regimens, the use of the CD200-CD200R pair as target sites to alleviate poststroke inflammatory injury is certainly one of the best options (). Regulation of microglia using the CD200-CD200R crosstalk meets our natural body rhythm in an even better way and enables our body to conduct efficient signal transmission and maintain the cells in a steady state. Considering this, it is a long and uphill journey to reveal more unknown details about the CD200-CD200R axis.
Statements
Author contributions
HS conceived the review. JL participated in drafting the manuscript. All authors wrote the manuscript.
Funding
This work was supported by the National Natural Science Foundation of China (81701243), the Pearl River S&T Nova Program of Guangzhou (201710010047), and the Presidential Foundation of Zhujiang Hospital of Southern Medical University (No. yzjj2018rc03).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AnratherJ.IadecolaC. (2016). Inflammation and stroke: an overview.Neurotherapeutics13661–670. 10.1007/s13311-016-0483-x
2
BiberK.NeumannH.InoueK.BoddekeH. W. (2007). Neuronal ‘On’ and ‘Off’ signals control microglia.Trends Neurosci.30596–602. 10.1016/j.tins.2007.08.007
3
BorlonganC. V.KanekoY.MakiM.YuS.-J.AliM.AllicksonJ. G.et al (2010). Menstrual blood cells display stem cell–like phenotypic markers and exert neuroprotection following transplantation in experimental stroke.Stem Cells Dev.19439–452. 10.1089/scd.2009.0340
4
CasoJ. R.PradilloJ. M.HurtadoO.LorenzoP.MoroM. A.LizasoainI. (2007). Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke.Circulation1151599–1608. 10.1161/CIRCULATIONAHA.106.603431
5
DeckertM.SedgwickJ. D.FischerE.SchluterD. (2006). Regulation of microglial cell responses in murine Toxoplasma encephalitis by CD200/CD200 receptor interaction.Acta Neuropathol.111548–558. 10.1007/s00401-006-0062-z
6
EckertA.HuangL.GonzalezR.KimH. S.HamblinM. H.LeeJ. P. (2015). Bystander effect fuels human induced pluripotent stem cell-derived neural stem cells to quickly attenuate early stage neurological deficits after stroke.Stem Cells Transl. Med.4841–851. 10.5966/sctm.2014-0184
7
FrechouM.Beray-BerthatV.RaynaudJ. S.MeriauxS.GombertF.LancelotE.et al (2013). Detection of vascular cell adhesion molecule-1 expression with USPIO-enhanced molecular MRI in a mouse model of cerebral ischemia.Contrast Media Mol. Imaging8157–164. 10.1002/cmmi.1512
8
GorczynskiR.ChenZ.KaiY.LeeL.WongS.MarsdenP. A. (2004). CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules.J. Immunol.1727744–7749. 10.4049/jimmunol.172.12.7744
9
GuixF. X.UribesalgoI.ComaM.MunozF. J. (2005). The physiology and pathophysiology of nitric oxide in the brain.Prog. Neurobiol.76126–152. 10.1016/j.pneurobio.2005.06.001
10
HayakawaK.PhamL. D.SeoJ. H.MiyamotoN.MakiT.TerasakiY.et al (2016). CD200 restrains macrophage attack on oligodendrocyte precursors via toll-like receptor 4 downregulation.J. Cereb. Blood Flow Metab.36781–793. 10.1177/0271678X15606148
11
HernangomezM.Carrillo-SalinasF. J.MechaM.CorreaF.MestreL.LoriaF.et al (2014). Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system.Curr. Pharm. Des.204707–4722. 10.2174/1381612820666140130202911
12
HoekR. M.RuulsS. R.MurphyC. A.WrightG. J.GoddardR.ZurawskiS. M.et al (2000). Down-regulation of the macrophage lineage through interaction with OX2 (CD200).Science2901768–1771. 10.1126/science.290.5497.1768
13
IadecolaC.AnratherJ. (2011). The immunology of stroke: from mechanisms to translation.Nat. Med.17796–808. 10.1038/nm.2399
14
Jimenez FernandezD.LamkanfiM. (2015). Inflammatory caspases: key regulators of inflammation and cell death.Biol. Chem.396193–203. 10.1515/hsz-2014-0253
15
KanazawaM.NinomiyaI.HatakeyamaM.TakahashiT.ShimohataT. (2017). Microglia and monocytes/macrophages polarization reveal novel therapeutic mechanism against stroke.Int. J. Mol. Sci.18:2135. 10.3390/ijms18102135
16
KimY. K.NaK. S.MyintA. M.LeonardB. E. (2016). The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression.Prog. Neuropsychopharmacol. Biol. Psychiatry64277–284. 10.1016/j.pnpbp.2015.06.008
17
KongT.ParkJ. M.JangJ. H.KimC. Y.BaeS. H.ChoiY.et al (2018). Immunomodulatory effect of CD200-positive human placenta-derived stem cells in the early phase of stroke.Exp. Mol. Med.50:e425. 10.1038/emm.2017.233
18
KongY.LeY. (2011). Toll-like receptors in inflammation of the central nervous system.Int. Immunopharmacol.111407–1414. 10.1016/j.intimp.2011.04.025
19
LagoN.PannunzioB.Amo-AparicioJ.Lopez-ValesR.PeluffoH. (2018). CD200 modulates spinal cord injury neuroinflammation and outcome through CD200R1.Brain Behav. Immun.73416–426. 10.1016/j.bbi.2018.06.002
20
LamkanfiM.DixitV. M. (2014). Mechanisms and functions of inflammasomes.Cell1571013–1022. 10.1016/j.cell.2014.04.007
21
LiuJ.HjorthE.ZhuM.CalzarossaC.SamuelssonE. B.SchultzbergM.et al (2013). Interplay between human microglia and neural stem/progenitor cells in an allogeneic co-culture model.J. Cell. Mol. Med.171434–1443. 10.1111/jcmm.12123
22
LiuY.BandoY.Vargas-LowyD.ElyamanW.KhouryS. J.HuangT.et al (2010). CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis.J. Neurosci.302025–2038. 10.1523/JNEUROSCI.4272-09.2010
23
ManichG.RecasensM.ValenteT.AlmoldaB.GonzalezB.CastellanoB. (2019). Role of the CD200-CD200R axis during homeostasis and neuroinflammation.Neuroscience405118–136. 10.1016/j.neuroscience.2018.10.030
24
MatzingerP. (2002). The danger model: a renewed sense of self.Science296301–305. 10.1126/science.1071059
25
MuJ.BakreenA.JuntunenM.KorhonenP.OinonenE.CuiL.et al (2019). Combined adipose tissue-derived mesenchymal stem cell therapy and rehabilitation in experimental stroke.Front. Neurol.10:235. 10.3389/fneur.2019.00235
26
OriaM.FigueiraR. L.ScorlettiF.SbragiaL.OwensK.LiZ.et al (2018). CD200-CD200R imbalance correlates with microglia and pro-inflammatory activation in rat spinal cords exposed to amniotic fluid in retinoic acid-induced spina bifida.Sci. Rep.8:10638. 10.1038/s41598-018-28829-5
27
PortegiesM. L.BosM. J.HofmanA.HeeringaJ.FrancoO. H.KoudstaalP. J.et al (2016). Role of prestroke vascular pathology in long-term prognosis after stroke: the rotterdam study.Stroke4780–87. 10.1161/STROKEAHA.115.011256
28
RenY.YeM.ChenS.DingJ. (2016). CD200 inhibits inflammatory response by promoting KATP channel opening in microglia cells in Parkinson’s disease.Med. Sci. Monitor221733–1741. 10.12659/msm.898400
29
RitzelR. M.Al MamunA.CrapserJ.VermaR.PatelA. R.KnightB. E.et al (2019). CD200-CD200R1 inhibitory signaling prevents spontaneous bacterial infection and promotes resolution of neuroinflammation and recovery after stroke.J. Neuroinflamm.16:40. 10.1186/s12974-019-1426-3
30
RitzelR. M.PatelA. R.GrenierJ. M.CrapserJ.VermaR.JellisonE. R.et al (2015). Functional differences between microglia and monocytes after ischemic stroke.J. Neuroinflamm.12:106. 10.1186/s12974-015-0329-1
31
RodriguesR. J.TomeA. R.CunhaR. A. (2015). ATP as a multi-target danger signal in the brain.Front. Neurosci.9:148. 10.3389/fnins.2015.00148
32
ShichitaT.HasegawaE.KimuraA.MoritaR.SakaguchiR.TakadaI.et al (2012). Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain.Nat. Med.18911–917. 10.1038/nm.2749
33
ValenteT.SerratosaJ.PerpinaU.SauraJ.SolaC. (2017). Alterations in CD200-CD200R1 system during EAE already manifest at presymptomatic stages.Front. Cell Neurosci.11:129. 10.3389/fncel.2017.00129
34
WalkerD. G.Dalsing-HernandezJ. E.CampbellN. A.LueL.-F. (2009). Decreased expression of CD200 and CD200 receptor in Alzheimer’s disease: a potential mechanism leading to chronic inflammation.Exp. Neurol.2155–19. 10.1016/j.expneurol.2008.09.003
35
WangJ. (2010). Preclinical and clinical research on inflammation after intracerebral hemorrhage.Prog. Neurobiol.92463–477. 10.1016/j.pneurobio.2010.08.001
36
WangX.-J.ZhangS.YanZ.-Q.ZhaoY.-X.ZhouH.-Y.WangY.et al (2011). Impaired CD200–CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: roles of aging, superoxide, NADPH oxidase, and p38 MAPK.Free Radic. Biol. Med.501094–1106. 10.1016/j.freeradbiomed.2011.01.032
37
WebbM.BarclayA. N. (1984). Localisation of the MRC OX-2 glycoprotein on the surfaces of neurones.J. Neurochem.431061–1067. 10.1111/j.1471-4159.1984.tb12844.x
38
WeinsteinJ. R.KoernerI. P.MollerT. (2010). Microglia in ischemic brain injury.Future Neurol.5227–246. 10.2217/fnl.10.1
39
WrightG. J.CherwinskiH.Foster-CuevasM.BrookeG.PuklavecM. J.BiglerM.et al (2003). Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.J. Immunol.1713034–3046. 10.4049/jimmunol.171.6.3034
40
WrightG. J.JonesM.PuklavecM. J.BrownM. H.BarclayA. N. (2001). The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans.Immunology102173–179. 10.1046/j.1365-2567.2001.01163.x
41
Writing GroupM.MozaffarianD.BenjaminE. J.GoA. S.ArnettD. K.BlahaM. J.et al (2016). Heart disease and stroke statistics-2016 update: a report from the american heart association.Circulation133:e38-360. 10.1161/CIR.0000000000000350
42
XiongX.-Y.LiuL.YangQ.-W. (2016). Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke.Prog. Neurobiol.14223–44. 10.1016/j.pneurobio.2016.05.001
43
YooJ.KimH. S.SeoJ. J.EomJ. H.ChoiS. M.ParkS.et al (2016). Therapeutic effects of umbilical cord blood plasma in a rat model of acute ischemic stroke.Oncotarget779131–79140. 10.18632/oncotarget.12998
44
ZhangS.WangX. J.TianL. P.PanJ.LuG. Q.ZhangY. J.et al (2011). CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson’s disease.J. Neuroinflamm.8:154. 10.1186/1742-2094-8-154
45
ZhouY.WangY.WangJ.Anne StetlerR.YangQ. W. (2014). Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation.Prog. Neurobiol.11525–44. 10.1016/j.pneurobio.2013.11.003
Summary
Keywords
stroke, microglia, neuroinflammation, CD200-CD200R interaction, clinical potential
Citation
Zhao X, Li J and Sun H (2019) CD200-CD200R Interaction: An Important Regulator After Stroke. Front. Neurosci. 13:840. doi: 10.3389/fnins.2019.00840
Received
29 April 2019
Accepted
26 July 2019
Published
07 August 2019
Volume
13 - 2019
Edited by
Mohammad Badruzzaman Khan, Medical College of Georgia, Augusta University, United States
Reviewed by
Rajaneesh K. Gupta, University of Pittsburgh, United States; Koteswara Rao Nalamolu, University of Illinois College of Medicine at Peoria, United States
Updates
Copyright
© 2019 Zhao, Li and Sun.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Haitao Sun, 2009sht@smu.edu.cn; msunhaitao1988@126.com
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.